Editorials

Health and economic policy

The idea that the health sector should collaborate in the development of policies in other sectors, such as transport, housing, or energy, is nowadays widely accepted in principle, if insufficiently in practice. "Intersectoral policy" is firmly in the books and worthy declarations not just of the World Health Organisation but of many countries.¹ In Britain, Glasgow, Belfast, Camden, and Liverpool have developed and implemented intersectoral policies through WHO's healthy cities project, and many other communities are participating in similar activities through the UK Health for All Network.

Intersectoral policy is not a bid for health to dictate policy in other sectors; it is an attempt to influence decisions so that avoidable casualties are prevented. For example, treatment services clearly have a role in dealing with the respiratory or other casualties of road traffic, but it is little consolation . . . [Full text of this article]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Article

New measures can help to measure economic "externalities"

Ed Mayo
BMJ 1995 311: 878. [Extract] [Full Text]

This article has been cited by other articles:

• Olanow, C. W., Myllyla, V. V., Sotaniemi, K. A., Larsen, J. P., Palhagen, S., Przuntek, H., Heinonen, E. H., Kilkku, O., Lammintausta, R., Maki-Ikola, O., Rinne, U. K. (1998). Effect of selegiline on mortality in patients with Parkinson's disease: A meta-analysis. Neurology 51: 825-830 [Abstract] [Full text]  
• Palhagen, S., Heinonen, E. H., Hagglund, J., Kaugesaar, T., Kontants, H., Maki-Ikola, O., Palm, R., Turunen, J., *Swedish Parkinson Study Group, (1998). Selegiline delays the onset of disability in de novo parkinsonian patients. Neurology 51: 520-525 [Abstract] [Full text]  
• Chase, T. N. (1998). Levodopa therapy: Consequences of the nonphysiologic replacement of dopamine. Neurology 50: S17-S25 [Abstract] [Full text]  
• (1998). Management of Parkinson's disease. Neurology 50: S2-S57 [Full text]  
• Khatri, A., Pearlstein, L. (1997). Pain in Guillain-Barre syndrome. Neurology 49: 1474-1474 [Full text]  
• Moulin, D. E., Hahn, A., Hagen, N., Feasby, T. E. (1997). Pain in Guillain-Barre syndrome. Neurology 49: 1474-1474 [Full text]  
• Stern, M. B. (1997). Contemporary approaches to the pharmacotherapeutic management of Parkinson's disease: An overview. Neurology 49: S2-S9 [Abstract] [Full text]  
• Olanow, C. W. (1997). Attempts to obtain neuroprotection in Parkinson's disease. Neurology 49: S26-S33 [Abstract] [Full text]  
• Tatton, W. G. (1996). Modulation of gene expression rather than monoamine oxidase inhibition: (-)-Deprenyl-related compounds in controlling neurodegeneration. Neurology 47: 171S-183S [Abstract] [Full text]  
• Koller, W. C. (1996). Selegiline monotherapy in the treatment of Parkinson's disease. Neurology 47: 196S-199S [Full text]  
• Myllyla, V. V., Sotaniemi, K., Maki-Ikola, O., Rinne, U. K., Heinonen, E. H. (1996). Role of selegiline in combination therapy of Parkinson's disease. Neurology 47: 200S-209S [Full text]  
• Olanow, C. W. (1996). Selegiline: Current perspectives on issues related to neuroprotection and mortality. Neurology 47: 210S-216S [Full text]  
• Jorgensen, H. S., Nakayama, H., Reith, J., Raaschou, H. O., Olsen, T. S. (1996). Factors delaying hospital admission in acute stroke: The Copenhagen Stroke Study. Neurology 47: 383-387 [Abstract] [Full text]  
• Rowbotham, M. C. (1995). Chronic pain: From theory to practical management. Neurology 45: S5-S10 [Abstract] [Full text]  
• Mayo, E. (1995). New measures can help to measure economic "externalities". BMJ 311: 878a-878 [Full text]